Xiaoning (Shelly) Wang, Ph.D.

Group Leader PKPD, Principal Scientist II

Shelly joined Metrum in 2018. She brings 11 years of pharmaceutical industry experience in the area of pharmacometrics. She earned her Ph.D. degree in Biomedical Engineering from the University of Southern California.

Shelly’s clinical experience includes clinical pharmacology in pediatrics, oncology, and immuno-science. She plans to continue her research in the application of pharmacokinetic and pharmacodynamic modeling and simulations in drug development.

Recent publications by this scientist

Application of Quantitative Modeling in the Optimization of Dosing Regimen for Oncology Drug Development

May 19, 2023

Shelly Wang presents a ProjectOptimus focused webinar focused on the use of MIDD in dose selection and optimization in oncology drug development. May 11, 2023.

Download PDF

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy

May 19, 2023

Hamim Zahir, Ophelia Yin, Ching Hsu, Andrew J. Wagner, Jason Jiang, Xiaoning Wang, Jon Greenberg, Dale E. Shuster, Tarundeep Kakkar, Frank LaCreta

First published: 21 March 2023

Read Article

Population Pharmacokinetic Analysis for Comparison of Pexidartinib Exposure in Asian and Non-Asian Patients

November 21, 2019

Chia-Chi Lin, Jun Guo, William D. Tap, Andrew J. Wagner, Silvia Stacchiotti, Jih-Hsiang Lee, Xiaoning Wang, Jia Kang, Hamim Zahir, Shun-ichi Sasaki, Ophelia Yin

Poster presented at the 2019 Connective Tissue Oncology Society annual meeting in Toyko, Japan. 14 Nov 2019